

## REMARKS/ARGUMENTS

This is intended as a full and complete response to the Office Action dated August 9, 2007. Please reconsider the claims pending in the application for reasons discussed below.

### DISPOSITION OF CLAIMS

Claims 59, 61-63, 69-72, and 81-87 are pending in this application. Claims 76-80 have been canceled. Claims 82-90 are new. Claims 82-89 are based on Examples 1 and 2 of the instant application. Claims 84 and 85 find support in original claims 7, 8, and 9. Claim 90 is based on Example 5. Claims 59, 61-63, 72, and 81 have been amended to depend from claim 82. No new matter has been added by these amendments. These amendments have been made in an effort to advance prosecution of this application.

### REJECTIONS UNDER 35 U.S.C. §103

Claims 59, 61-63, 69-72, and 76-81 stand rejected under 35 U.S.C. § 103 as being unpatentable over Rudnic et al. (U.S. Patent No. 5,952,004) in view of Eckenhoff et al. (U.S. Patent No. 4,692,326) and Al-Razzak et al. (U.S. Patent No. 5,559,158). Claims 76-80 have been cancelled. Accordingly, the rejection of these claims is moot. Reconsideration of the rejection of claims 59, 61-63, 69-72, and 81 is respectfully requested.

Claims 59, 61-63, 69-72, and 81 ultimately depend from new claim 82. Rudnic et al. taken in combination with Eckenhoff et al. and Al-Razzak et al. do not disclose or teach a sustained release oral dosage form as recited in claim 82. In particular, Rudnic et al. taken in combination with Eckenhoff et al. and Al-Razzak et al. do not disclose or teach, "a liquid antiviral drug composition included in the capsule, the liquid antiviral drug composition comprising nelfinavir as an antiviral drug and polyoxyethylene 20 sorbitan monooleate as a solvent for the antiviral drug," as recited in claim 82.

From the foregoing, claim 82 is not obvious over Rudnic et al. in view of Eckenhoff et al. and Al-Razzak et al. Claims 59, 61-63, and 69-72, being ultimately

dependent from claim 82, are also not obvious over Rudnic et al. in view of Eckenhoff et al. and Al-Razzak et al. Withdrawal of the rejection of claims 59, 61-63, 69-72, and 81 over the combination of these references is respectfully requested.

CONCLUSION

Applicant believes that this paper is fully responsive to the Office Action dated August 9, 2007. A call to the undersigned is encouraged if the Examiner believes that a telephone conference would advance prosecution of this application.

Date: January 9, 2008

Respectfully submitted,  
DEWIPAT Incorporated  
By /Adenike Adebiyi, Reg. No. 42254/  
Adenike A. Adebiyi  
Agent for Applicant  
Reg. No. 42,254  
Tel.: (281) 856-8646